ECHO-COPD: Impact of a Pharmacist-Led Health Belief Model-Based Educational Intervention Among Chronic Obstructive Pulmonary Disease Patients (ECHO-COPD)
Impact of a Pharmacist-Led Health Belief Model-Based Educational Intervention on Medication Adherence, Quality of Life, and Direct Costs in Patients With Chronic Obstructive Pulmonary Disease: A Quasi-Experimental Study
Chronic obstructive pulmonary disease (COPD) is a chronic respiratory disease associated with substantial morbidity and mortality, impaired quality of life, and healthcare costs. Medication adherence and appropriate self-management are important components of COPD management; however, patients' health beliefs and perceptions may influence their adherence to treatment and engagement in recommended health behaviours. This study aims to evaluate the impact of a pharmacist-led educational intervention based on the Health Belief Model (HBM) on medication adherence, quality of life, and direct healthcare costs among patients with COPD receiving care at Buraidah Central Hospital (BCH) in Al-Qassim Region, Saudi Arabia. This study will use a quantitative, quasi-experimental pretest-posttest control-group design. Eligible COPD patients will be non-randomly assigned to either an intervention group or a control group. The intervention group will receive structured, pharmacist-led HBM-based educational sessions in addition to routine care. In contrast, the control group will receive standard care without additional education. Baseline assessments will include medication adherence using the Morisky Medication Adherence Scale-8 (MMAS-8); quality of life and health status using the COPD Assessment Test (CAT); health beliefs using a structured HBM questionnaire; and direct medical costs obtained from the hospital clinical cost centre. The educational intervention will be delivered over six months, followed by post-intervention assessment using the same outcome measures.
調査の概要
状態
詳細な説明
The Health Belief Model (HBM) will guide the content and delivery of the pharmacist-led educational intervention. The intervention will address six core HBM constructs: perceived susceptibility, perceived severity, perceived benefits, perceived barriers, cues to action, and self-efficacy. The purpose of applying the HBM is to improve patients' understanding of chronic obstructive pulmonary disease (COPD) and promote positive behavioural changes, particularly improved medication adherence.
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:Bander S Alshammeri, MSc
- 電話番号:+966509466669
- メール:bandershe3@gmail.com
研究連絡先のバックアップ
- 名前:Rabia Hussain, PhD, Lecturer
- 電話番号:+6046534085
- メール:rabia.hussain@usm.my
研究場所
-
-
Al-Qassim Region
-
Buraidah、Al-Qassim Region、サウジアラビア、52391
- Bander S Alshammeri
-
コンタクト:
- Bander S Alshammeri, MSc
- 電話番号:+966509466669
- メール:bandershe3@gmail.com
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
Participants must:
- Be adults aged 18-65 years.
- Be diagnosed with chronic obstructive pulmonary disease (COPD) stages I-III according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines.
- Have visited or been admitted for a COPD exacerbation and are receiving care at Buraidah Central Hospital (BCH) in Al-Qassim Region, Saudi Arabia.
- Be Arabic-speaking and capable of understanding study instructions.
- Be willing and able to provide written informed consent.
Exclusion Criteria:
Participants will be excluded if they:
- Are diagnosed with COPD stage IV.
- Have another significant pulmonary disease, including: Asthma, bronchiectasis, pneumonia, or cystic fibrosis.
- Have a serious systemic illness, severe comorbidity, or central organ dysfunction, including: Hepatic dysfunction, renal dysfunction, psychiatric impairment or sensory impairment.
- Are immunocompromised or receiving immunosuppressive treatment.
- Have psychological, sensory, or cognitive impairment that prevents meaningful participation in the study.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:ヘルスサービス研究
- 割り当て:非ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:HBM-Based Educational Intervention
Participants in the intervention group will receive routine care together with structured pharmacist-led educational sessions based on the HBM. The educational intervention will be conducted face-to-face during scheduled outpatient appointments in the designated counselling room of the Pulmonary Department. The programme will be delivered from study months 4 to 9. Educational sessions will include:
|
Participants in the intervention group will receive routine care together with structured pharmacist-led educational sessions based on the HBM. The educational intervention will be conducted face-to-face during scheduled outpatient appointments in the designated counselling room of the Pulmonary Department. The programme will be delivered from study months 4 to 9. Educational sessions will include:
|
|
介入なし:Standard Care
Participants in the control group will continue to receive routine/standard care provided by BCH. They will not receive the additional structured pharmacist-led HBM-based educational intervention. Both intervention and control participants will undergo the same baseline and post-intervention assessments. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Medication Adherence
時間枠:Baseline and 6 months after initiation of the educational intervention.
|
Outcome Measure: Change in Medication Adherence Assessed by the Morisky Medication Adherence Scale-8. Measurement Tool: Morisky Medication Adherence Scale-8 (MMAS-8), prevalidated Arabic version. The MMAS-8 is an 8-item self-reported measure of medication-taking behaviour, with a total score ranging from 0 to 8. Higher scores indicate better medication adherence, whereas lower scores indicate poorer adherence. Scores are commonly classified as low adherence (<6), medium adherence (6 to <8), and high adherence (8). |
Baseline and 6 months after initiation of the educational intervention.
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Quality of Life and Health Status
時間枠:Baseline and 6 months after initiation of the educational intervention.
|
Outcome Measure: Change in Health Status Assessed by the COPD Assessment Test (CAT). Description: The prevalidated Arabic COPD Assessment Test (CAT) will be used to assess health status in patients with chronic obstructive pulmonary disease. The CAT contains 8 items, each scored from 0 to 5, giving a total score range of 0-40. Higher scores indicate a greater impact of COPD on health status and therefore a worse outcome; lower scores indicate better health status. |
Baseline and 6 months after initiation of the educational intervention.
|
|
Direct Healthcare Costs
時間枠:Direct medical costs assessed during the pre-intervention baseline period and during the post-intervention follow-up period after completion of the six-month intervention.
|
Change in direct medical costs associated with COPD Direct healthcare cost data will be obtained from the clinical cost centre of Buraidah Central Hospital (BCH). The costing analysis will include direct COPD-related healthcare resources such as:
Important Costing Specification The cost of delivering the educational intervention will not be included in the costing analysis. The economic component of this study focuses on the direct cost of illness associated with COPD rather than the cost of implementing the educational intervention. |
Direct medical costs assessed during the pre-intervention baseline period and during the post-intervention follow-up period after completion of the six-month intervention.
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
HBM Constructs
時間枠:Baseline and 6 months after initiation of the educational intervention.
|
Outcome Measure: Change in Health Beliefs Assessed by the Health Belief Model (HBM) Questionnaire. Description: A prevalidated Arabic Health Belief Model (HBM) questionnaire will assess six constructs using a 3-point Likert scale (Disagree=0, Neutral=1, Agree=2). Perceived susceptibility: 3 items, range 0-6; severity: 5 items, 0-10; benefits: 3 items, 0-6; barriers: 5 items, 0-10; cues to action: 5 items, 0-10; self-efficacy: 5 items, 0-10. Higher scores indicate greater levels of the respective construct. For perceived barriers, higher scores indicate more barriers and therefore a less favourable outcome. |
Baseline and 6 months after initiation of the educational intervention.
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- USM-DSAP-2026-002
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。